The X-Change Corporation Continues New Product Development Progress Simultaneously with European Line and Extract-Based Products

DALLAS, May 20, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health solutions through its Phytiva brand product lines is excited to confirm continued emphasis on new product development beyond recently announced European and extract-based lines. One of the several opportunities being explored by the Company is a new retail product line developed in conjunction with Steven B. Hopping, M.D., F.A.C.S., renowned cosmetic surgeon and Senior Medical Advisor of X-Change Corp. All of the Company's products will be available through the store at the Company's newly upgraded website at, launched last week with its innovative Patient Resource Center for sharing of information on a patient-to-patient basis.

Dr. Hopping joined the X-Change Corp team earlier this year. The Company's chief operating officer, Chad Johnson, was involved with Dr. Hopping's surgical and skincare practice for years prior to joining the Company. The Company and Dr. Hopping are discussing the expansion of their respective product lines to meet the increasing demand for affordable, high-end, anti-aging and therapeutic skin care treatments. Consumer awareness has significantly increased among women and men of all ages that quality formulations enhance skin health and appearance, and the Company believes that a joint venture between the Company and Dr. Hopping would be mutually advantageous and a great addition to product offerings already in the pipeline.

"As we move quickly to market with the Company's European Line of products and extracts, we continue to seek out additional opportunities in the skincare and related markets worldwide," said Chad Johnson, X-Change Corp. Chief Operating Officer. "As the Company's profile grows, so do the opportunities available to the Company to enhance currently planned product development and marketing. In addition to discussions with Dr. Hopping about a new line is an opportunity that would target the consumers of Central and South America. More details will be forthcoming on this later this quarter."

About Steven B. Hopping, M.D., F.A.C.S.
Dr. Steven B. Hopping received his specialty training at Harvard University and has been practicing cosmetic surgery for over 20 years, assisting patients across the United States and around the world. Dr. Hopping is Board Certified by three separate surgical boards: The American Board of Cosmetic Surgery, The American Board of Facial Plastic and Reconstructive Surgery, and The American Board of Otolaryngology, Head and Neck Surgery. He is also a Diplomate of the American Board of Hair Restoration. Dr. Hopping is the Medical Director of The Center for Cosmetic Surgery and of the Washington Hair Institute in Washington, DC. He also has an active practice in Dubai. Dr. Hopping is a Clinical Professor of Surgery at George Washington University and is regarded by his peers as a highly talented and innovative cosmetic surgeon. He lectures at numerous national and international conferences each year and is recognized around the world as both a leader and innovator in the cosmetic sector. Dr. Hopping has written numerous articles and been published in medical journals related to advances in cosmetic surgery, and is frequently sought out by the media as an authority in his field.

About Phytiva Brand Product Lines
Phytiva expects to develop and launch various innovative product lines. The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a cannabinoid based product line, utilizing the unique and potent benefits of cannabinoids. Phytiva's revolutionary formulations target not just the symptom, but also the cause. Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies for human ailments.

About The X-Change Corporation
X-Change Corp. is a U.S. Company specializing in cannabinoid based extracts and products that target medical cannabis, nutraceutical, cosmeceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services. These new Phytiva lines will be launched with cannabinoid based formulations through the launching of a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, and other legal state and foreign grow operations, on a jurisdiction by jurisdiction approved basis.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.
President & CEO
Robert Kane
This email address is being protected from spambots. You need JavaScript enabled to view it.